Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

This study has been terminated.
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00083486
First received: May 24, 2004
Last updated: April 25, 2011
Last verified: April 2011

May 24, 2004
April 25, 2011
February 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00083486 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
Not Provided

The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.

Not Provided
Interventional
Phase 3
Primary Purpose: Treatment
Anemia
Drug: epoetin alfa
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
Not Provided
October 2004
Not Provided

Inclusion Criteria:

  • Body weight >/=99 lbs
  • ECOG 0-2
  • Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
  • Screening hemoglobin level of </=11.0 g/dL for men or </=10.0 for women
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00083486
CR010939, EPO-CAN-203
Not Provided
Not Provided
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not Provided
Not Provided
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP